Funding the Development and Manufacturing of COVID-19 Vaccines

Background paper for the World Bank/CEPI financing COVID-19 vaccine development consultation on February 20, 2020. The Center for Policy Impact in Global Health.

Duke Global Working Paper Series No. 20, March 2020

27 Pages Posted: 14 Apr 2020

See all articles by Gavin Yamey

Gavin Yamey

Duke Global Health Institute

Marco Schäferhoff

Open Consultants

Muhammad Pate

World Bank

Mukesh Chawla

Harvard University - T.H. Chan School of Public Health

Kent Ranson

World Bank - Geneva

Richard Hatchett

Coalition for Epidemic Preparedness Innovations

Richard Wilder

Coalition for Epidemic Preparedness Innovations

Abstract

The SARS-CoV-2 virus, which causes COVID-19, has quickly spread worldwide. On January 30, 2020, the WHO declared COVID-19 to be a Public Health Emergency of International Concern and advised all governments to prepare for transmission in their countries. On March 11, 2020, the WHO declared that it had become a pandemic. There is uncertainty about what will happen next, e.g., the pandemic could involve multiple simultaneous epidemics of COVID-19 over 1-3 years, and/or SARS-CoV-2 could become a globally endemic virus. In this paper, we begin by arguing that the rapid development and scale-up of COVID-19 vaccines has become critical to reducing the morbidity, mortality, and economic damage associated with a pandemic. We show that new funding for COVID-19 vaccine development is required for all development stages and we estimate how much funding is needed. We examine ways to mobilize such funding and explore potential funding vehicles, including CEPI, the Coalition for Epidemic Preparedness Innovations, as well as the governance of such vehicles. Finally, we highlight issues such as vaccine manufacturing, intellectual property, global access, regulatory approval, and ethical and trial design considerations in conducting trials in the midst of the COVID-19 outbreak.

Keywords: COVID-19, pandemic, vaccine, infectious diseases, research and development, clinical trials

Suggested Citation

Yamey, Gavin and Schäferhoff, Marco and Pate, Muhammad and Chawla, Mukesh and Ranson, Kent and Hatchett, Richard and Wilder, Richard, Funding the Development and Manufacturing of COVID-19 Vaccines. Background paper for the World Bank/CEPI financing COVID-19 vaccine development consultation on February 20, 2020. The Center for Policy Impact in Global Health.; Duke Global Working Paper Series No. 20, March 2020. Available at SSRN: https://ssrn.com/abstract=3575660 or http://dx.doi.org/10.2139/ssrn.3575660

Gavin Yamey (Contact Author)

Duke Global Health Institute ( email )

Trent Hall
310 Trent Drive
Durham, NC 27708
United States

Marco Schäferhoff

Open Consultants ( email )

Cantianstr. 22
Berlin, Berlin 10437
Germany

Muhammad Pate

World Bank

1818 H Street, NW
Washington, DC 20433
United States

Mukesh Chawla

Harvard University - T.H. Chan School of Public Health

677 Huntington Avenue
Boston, MA MA 02115
United States

Kent Ranson

World Bank - Geneva ( email )

ch. Louis-Dunant 3
C.P. 66
1211 Geneva 20, 1202
Switzerland

Richard Hatchett

Coalition for Epidemic Preparedness Innovations ( email )

United States

Richard Wilder

Coalition for Epidemic Preparedness Innovations ( email )

United States

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
98
Abstract Views
477
rank
289,499
PlumX Metrics